The Medication(s) listed below have been approved by the Food & Drug Administration (FDA) as orphan products for treatment of this condition. There may be other products available
that are not considered orphan products.
Ravulizumab-cwvz (Brand name: Ultomiris)
- Manufactured by
Alexion Pharmaceuticals, Inc.
FDA-approved indication: December 2018, ravulizumab-cwvz (Ultomiris) was approved for the treatment of adult patients with paroxysmal nocturnal hemoglobinuria (PNH).
National Library of Medicine Drug Information Portal